CClinicalTrials.gg
Status unknownNCT03313934Updated Oct 18, 2017

Platelet Rich Fibrin for Tear Trough Rejuvenation

An Early Phase 1 interventional study of Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF) and Hyaluronic Acid Filler and Saline in Tear Trough Hollowing, Under Eye Bags, sponsored by Rejuva Medical Aesthetics. Status unknown at 1 site in United States. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-18.

Sponsored by Rejuva Medical Aesthetics · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the efficacy and longevity of Platelet Rich Fibrin (PRF) in combination with hyaluronic acid filler for cosmetic volume restoration of the tear troughs. This study will also evaluate visible improvement in skin texture that may be attributable to the added PRF.

Read the detailed description

Background: Platelet therapy is quickly becoming an integral aspect of cosmetic treatments. Most notably, Platelet Rich Plasma (PRP) has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis. Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. This is useful in reconstructive and aesthetic medicine, which allows it to be used for cosmetic volume restoration in addition to topical indications.

Hyaluronic acid fillers have become increasingly popular in aesthetic medicine over the past two decades. Hyaluronic acid fillers are synthesized in a variety of different ways and last anywhere from 6 to 24 months, depending on the volume and location of the face or body they are injected. Fillers under the eyes in the "tear trough" area are popular treatments to allow patients to appear more refreshed and rested. Although this is an "off label" application of injectable fillers, it is extremely popular and is performed safely in many aesthetic clinics worldwide. Given that PRF can be used to restore volume, it will be determined if PRF in combination with hyaluronic acid filler will enhance resultant volume and skin quality in the treated areas.

Objective: The purpose of this study is to investigate the efficacy and longevity of Platelet Rich Fibrin (PRF) in combination with hyaluronic acid filler for cosmetic volume restoration of the tear troughs. This study will also evaluate visible improvement in skin texture that may be attributable to the added PRF.

Hypothesis: The addition of Platelet Rich Fibrin (PRF) to hyaluronic acid fillers contribute to volume restoration of the tear trough and also improve the texture and quality of the skin in the treated area. The patient will perceive a more natural and improved result on the PRF-treated side.

02

Conditions studied

  • Tear Trough Hollowing, Under Eye Bags

Keywords

  • Hyaluronic Acid Filler
  • Platelet Rich Fibrin (PRF)
  • Tear Trough Filler
03

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Males/females aged 20-80 who are experiencing moderate volume loss of the tear troughs and/or under eye bags. Eligible subjects will be in generally good health and able to provide a blood sample for treatment.

Exclusion criteria

Exclusion Criteria:

  • Those who fall outside of the age range 20-80 years of age, with chronic health problems including but not limited to thyroid disorders, cancer, blood disease, etc. Those who do not demonstrate volume loss of the tear troughs to the degree that warrants intervention. Conversely, those who are better suited for surgical intervention as opposed to non-surgical injections will not be eligible.
04

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Placebo comparator
    Hyaluronic Acid Filler with Saline

    For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.

    Combination Product: Hyaluronic Acid Filler and Saline

  • Experimental
    Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)

    For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.

    Combination Product: Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)

Interventions

  • Combination productHyaluronic Acid Filler and Platelet Rich Fibrin (PRF)

    The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.

    Also known as: Restylane-L

  • Combination productHyaluronic Acid Filler and Saline

    This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.

    Also known as: Restylane-L

05

What researchers measure

Primary outcomes

  1. Overall Tear Trough Rejuvenation

    Restoration of volume loss and improved skin quality of the tear troughs

    Time frame: 1 month

  2. Improvement of Facial Rhytids

    Reduction in wrinkles and appearance of "crepey" skin.

    Time frame: 12 months

06

Study locations

1 site
  • Rejuva Medical Aesthetics
    Los Angeles, California 90025, United States
07

References and documents

Individual participant data

Plan to share: Undecided — The data will be collected, organized, and summarized in a manuscript to be submitted for publication. The publication will be available for other researchers to review.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03313934
Lead sponsor
Rejuva Medical Aesthetics
Responsible party
Alex Reivitis (Clinical Research Coordinator, Rejuva Medical Aesthetics) — Principal investigator
First posted
Oct 18, 2017
Start date
Nov 2017 (estimated)
Primary completion
Nov 2018 (estimated)
Completion
Nov 2018 (estimated)
Last update
Oct 18, 2017

Study contacts

Alex N Reivitis, BA
Contact
alex@rejuvamedical.org
4246442400
Sherry Leigh, BA
Contact
sherry@rejuvamedical.org
8187269917
Kian Karimi, MD,FACS
principal investigator · Rejuva Medical Aesthetics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion